Showing results (81-90 of 235) with videos related to

Sort By:
Pageof 24
Urologic Oncology|March 10, 2018
The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancerIslam M El-Babouly, Esam A E Desoky, Diab El Sayed, et al.
American Journal of Hypertension|January 3, 2007
The G-231A polymorphism in the endothelin-A receptor gene is associated with lower aortic pressure in patients with dilated cardiomyopathyRalph Telgmann, Bassam A Harb, Cemil Ozcelik, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway RegulationReem A Qannita, Ayah I Alalami, Amani A Harb, et al.
Annals of Hematology|October 19, 2013
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myelomaJames R Berenson, James D Hilger, Ori Yellin, et al.
European Radiology|February 19, 2021
The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective studyMaha Ibrahim Metwally, Nesma Adel Zeed, Enas Mahmoud Hamed, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 20, 2023
PYCR1, BANF1, and STARD8 Expression in Gastric Carcinoma: A Clinicopathologic, Prognostic, and Immunohistochemical StudyOla A Harb, Mariem A Elfeky, Mohamed Ali Alabiad, et al.
Food Science & Nutrition|January 13, 2025
Exploring the Anticancer Effect of Artemisia herba-alba on Colorectal Cancer: Insights From Eight Colorectal Cancer Cell LinesLara J Bou Malhab, Amani A Harb, Leen Eldohaji, et al.
Advances in Therapy|October 26, 2013
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisDenise A Yardley, Shinzaburo Noguchi, Kathleen I Pritchard, et al.
Cancer|July 23, 2020
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179Greg A Durm, Salma K Jabbour, Sandra K Althouse, et al.
The Oncologist|April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.
Pageof 24